TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3310631
Drug: Sucralfate therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate therapy, 1 g four times daily
Study: 3310631
Drug: Sucralfate therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate therapy, 1 g twice daily to 1 g four times daily (long-term)
Study: 29895557
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment without empagliflozin)
Study: 27183970
Drug: Vectra® 3D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vectra® 3D (54.45 mg/ml of dinotefuran, 396.88 mg/ml of permethrin and 4.84 mg/ml of pyriproxyfen)
Study: 21040167
Drug: Post-transplantation dosing
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation dosing guided by a 2-hour (C(2) ) level (T2 group)
Study: 21040167
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (control group)
Study: 11305226
Drug: Intraoral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral appliance therapy (daily use) during Phase I (6 months) and Phase II (6 months)
Study: 11305226
Drug: Intraoral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral appliance therapy (daily use) during Phase II (6 months)
Study: 11305226
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (6 months prior to treatment)
Study: 11305226
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I and Phase II of intraoral appliance therapy
Study: 7949185
Drug: Standard Risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Risk Group (SRG) with reinduction therapy
Study: 7949185
Drug: Standard Risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Risk Group (SRG) without reinduction therapy
Study: 3190994
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 20 mg pholcodine
Study: 3190994
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 60 mg pholcodine
Study: 3190994
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of 20 mg pholcodine 8 hourly for 10 days
Study: 30946381
Drug: Ropivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine group (0.5% ropivacaine, 40 mL, n=69)
Study: 30946381
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no analgesic, n=63)
Study: 28968871
Drug: Standard-dose, egg‐grown,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose, egg‐grown, quadrivalent‐inactivated influenza vaccine (IIV4)
Study: 25304132
Drug: Tralokinumab 300
Normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab 300 mg subcutaneously every 2 weeks for 12 weeks
Study: 16861255
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide + 8 mg dexamethasone
Study: 16861255
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg metoclopramide + 8 mg dexamethasone
Study: 16861255
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoclopramide + 8 mg dexamethasone
Study: 16861255
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg metoclopramide + 8 mg dexamethasone
Study: 12508269
Drug: Short, intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short, intensive therapy (CCG-5911)
Study: 12508269
Drug: Moderate-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose chemotherapy (previous studies)
Study: 12508269
Drug: Elevated LDH
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated LDH (> or = 500 IU/L) at diagnosis and young age (<5 years)
Study: 10685739
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg for 6 weeks)
Study: 10685739
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg for 6 weeks)
Study: 10561203
Drug: Formestane (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formestane (250 mg intramuscularly biweekly)
Study: 10561203
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (160 mg orally daily)
Study: 8227233
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg conventional metoprolol (M100)
Study: 8227233
Drug: 50 or
Normalized name: Fe 50 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 or 100 mg slow-release metoprolol CR (CR50, CR100)
Study: 30846557
Drug: Tenapanor (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (3 mg)
Study: 30846557
Drug: Tenapanor (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (10 mg)
Study: 30846557
Drug: Tenapanor (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor (30 mg, down-titrated)
Study: 25772512
Drug: Standardized therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized therapy with traditional Chinese medicine
Study: 25772512
Drug: Individualized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized therapy with traditional Chinese medicine
Study: 25772512
Drug: Best supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care with traditional Chinese medicine
Study: 25772512
Drug: NCCN NSCLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCCN NSCLC treatment guidelines (Control group)
Study: 21532952
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment (2000, 4000, or 8000 lux for 1, 2, or 3 hours)
Study: 12895189
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen (single oral dose)
Study: 11990269
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine
Study: 30246748
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine (CHX) gel
Study: 22661508
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day) for 1 month in statin-naïve patients
Study: 19307970
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg and 0.2 mg morphine
Study: 15185764
Drug: Endovascular stent
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular stent treatment
Study: 3382462
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nimodipine
Study: 3382462
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nimodipine
Study: 23910069
Drug: Mivacurium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium 0.25 mg·kg(‐1) (NMB group)
Study: 23910069
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (NoNMB group)
Study: 16377964
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg of alcohol preload
Study: 16377964
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg of alcohol preload
Study: 12843164
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (25 mg/d)
Study: 10639301
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose amiodarone
Study: 10639301
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amiodarone
Study: 1505605
Drug: Computer-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosing of theophylline (437 mg loading dose)
Study: 1505605
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unaided physicians dosing of theophylline, 167 mg loading dose)
Study: 1505605
Drug: Computer-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosing of theophylline (613 mg loading dose for patients not previously on theophylline)
Study: 1505605
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 mg loading dose for patients not previously on theophylline)
Study: 6381556
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride at a dosage of 150 mg at bedtime
Study: 25445859
Drug: benralizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: benralizumab (0.3 mg/kg and 1.0 mg/kg)
Study: 24071578
Drug: Single 400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400-mg oral dose of ribavirin
Study: 19625981
Drug: Social Effectiveness
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Effectiveness Therapy for Children
Study: 9728845
Drug: IV amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amino acid infusion at the rate of 126 mL/h throughout anesthesia
Study: 9728845
Drug: Nutrient‐free saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient‐free saline infusion
Study: 31647185
Drug: IncobotulinumtoxinA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA treatment (400 U at 12-week intervals)
Study: 30342297
Drug: Combined effect
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined effect of aspirin and the Polycap
Study: 30342297
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for aspirin and vitamin D)
Study: 26185179
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg ephedrine, twice daily
Study: 11003446
Drug: Grass-pollen immunotherapy
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass-pollen immunotherapy
Study: 11003446
Drug: Birch-pollen immunotherapy
Normalized name: cherry birch pollen extract
DrugBank: Betula lenta pollen (DB10352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch-pollen immunotherapy
Study: 9087388
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of lymphokine-activated killer (LAK) cells (2 to 9 x 10^8) and recombinant interleukin-2 (rIL-2) (10^6 IU) weekly for four cycles, plus subcutaneous rIL-2 (3 x 10^6 IU/day for 24 days)
Study: 6117466
Drug: Strophanthin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strophanthin (0.5 mg)
Study: 6117466
Drug: Practolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (10 mg)
Study: 4877600
Drug: Propranolol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (4 mg)
Study: 6117466
Drug: Strophanthin compared
Normalized name: g-strophanthin
DrugBank: Ouabain (DB01092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strophanthin compared to β-blockers (Practolol and Propranolol)
Study: 6117466
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Strophanthin, Practolol, Propranolol)
Study: 28816136
Drug: No Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Music Therapy (no-MT)
Study: 21228786
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg per day)
Study: 21228786
Drug: Perindopril/Indapamide (2/0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril/Indapamide (2/0.6 mg per day)
Study: 19856795
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (500 mg azithromycin tablet - Zycin)
Study: 19856795
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (500 mg azithromycin)
Study: 19856795
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (500 mg azithromycin tablet - Zycin) vs Reference drug (500 mg azithromycin)
Study: 17145426
Drug: 2500 IU
Normalized name: Vitamin A/Vitamin D 2500 IU-270 IU Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137)
Study: 17145426
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin daily alone (n = 138)
Study: 7545577
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 12 IU/m2 per week
Study: 7545577
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 18 IU/m2 per week
Study: 7545577
Drug: Oxandrolone (Ox)
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone (Ox) after GH treatment
Study: 7545577
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) after GH treatment
Study: 1963014
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg subcutaneously twice daily for 14 days)
Study: 6217577
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg/day) for one month
Study: 12631093
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg/day)
Study: 27999106
Drug: 10‐h overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐h overnight GCG infusion (6 ng/[kg × min]) followed by 3‐h infusion of GCG, octreotide (OCT), and insulin (INS)
Study: 27999106
Drug: Overnight saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight saline (SAL) infusion followed by GCG/OCT/INS infusion
Study: 27999106
Drug: Overnight saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight saline (SAL) infusion followed by SAL/OCT/INS infusion
Study: 21255431
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga program (12 - 1.5 hour sessions twice weekly for 6 weeks)
Study: 10914850
Drug: Steroid treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid treated groups (exercise vs usual care)
Study: 29749363
Drug: Unani treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unani treatment (oral UNIM-401 and topical UNIM-403)
Study: 24452673
Drug: Sequential induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential induction chemotherapy and radiotherapy (control)
Study: 9463180
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg/day for 6 months)
Study: 9463180
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg twice daily for 6 months)
Study: 29659631
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 gram) IV preoperatively followed by two postoperative doses 6 hours apart
Study: 29659631
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 gram) IV
Study: 27251517
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) administered under endoscopic therapy
Study: 23525983
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitafloxacin once daily (100 mg qd group)
Study: 23525983
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sitafloxacin twice daily (50 mg bid group)
Study: 20637457
Drug: Flexible GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible GnRH antagonist administration (started when LH >10 IU/L, or follicle >12 mm, or serum E(2) >150 pg/mL)
Study: 20637457
Drug: Fixed GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed GnRH antagonist administration (started on day 6 of stimulation)
Study: 16499576
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine delivery (OptiMist device, nasal drops)
Study: 16499576
Drug: Oral spray
Normalized name: Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral spray immunization
Study: 10478148
Drug: Agarose gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agarose gel electrophoresis (AGE)
Study: 8917826
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream formulation 1
Study: 8917826
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream formulation 2
Study: 8917826
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream formulation 3
Study: 6981593
Drug: Iontophoretic application
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophoretic application of Placenta‐Lucchini in combination with catalase and mucopolysaccharidase
Study: 28210935
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation (15 ml kg‐1 fluid in 30 min)
Study: 24590751
Drug: Textual information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textual information about the dangers of the diseases prevented by MMR from the Vaccine Information Statement
Study: 24590751
Drug: Images of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Images of children who have diseases prevented by the MMR vaccine
Study: 16219122
Drug: Medications alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications alone
Study: 10519936
Drug: Hib-tetanus toxoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-tetanus toxoid conjugate vaccine (Hib-T)
Study: 10519936
Drug: DT- IPV
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DT- IPV mixed vaccine
Study: 2074087
Drug: GHRH(1-44)NH2, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH(1-44)NH2, 1 and 2 microgram/kg administered in random order
Study: 6947118
Drug: Intermittent combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent combination chemotherapy at 4-week intervals
Study: 6947118
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with neuraminidase-modified allogeneic blast cells
Study: 6418549
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g mezlocillin single-dose prophylaxis given immediately before surgery
Study: 6418549
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g mezlocillin single-dose prophylaxis
Study: 28157084
Drug: Massage (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage (15 minutes, twice a week for 4 weeks, total of 8 sessions)
Study: 23175341
Drug: Itraconazole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 200 mg daily for six weeks
Study: 23175341
Drug: Itraconazole treatment
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole treatment
Study: 10824717
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg)
Study: 7793192
Drug: Intramuscular morphine-scopolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine-scopolamine (0.15 +/- 0.006 mg x kg-1)
Study: 7793192
Drug: Rectal hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal hydrogel of morphine-scopolamine (0.25 +/- 0.015 mg x kg-1)
Study: 23463483
Drug: Rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.9 mg · kg(‐1)
Study: 20848578
Drug: Group Exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Exercise Therapy
Study: 12641635
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg progesterone intramuscularly (i.m.)
Study: 12641635
Drug: 300 micro
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micro g desogestrel orally daily for 7 days
Study: 9262495
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g per day) during lactation
Study: 9262495
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g per day) after weaning
Study: 12818462
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g per day)
Study: 3632762
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.5 g oil/10 kg b.wt./day for three weeks)
Study: 3632762
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (1.5 g oil/10 kg b.wt./day for three weeks)
Study: 28363933
Drug: Melatonin 2
Normalized name: melatonin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 2 mg
Study: 26185909
Drug: Thalidomide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 1.5 to 2.5 mg/kg/day
Study: 21040412
Drug: IGF-I treatment
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I treatment (50 μg/kg, twice daily for 7 days)
Study: 22932751
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline injections)
Study: 18976450
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A (docetaxel 70 mg/m2 on day 1 and gemcitabine 900 mg/m2 on days 3-8, every 3 weeks)
Study: 18976450
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (gemcitabine 900 mg/m2 on days 1 and 8, and docetaxel 70 mg/m2 on day 8, every 3 weeks)
Study: 11113492
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (0.3 mg administered 3.5 h after nicotine withdrawal)